59,983 Shares in Avanos Medical, Inc. $AVNS Purchased by SG Americas Securities LLC

SG Americas Securities LLC acquired a new stake in Avanos Medical, Inc. (NYSE:AVNS) in the 3rd quarter, HoldingsChannel.com reports. The institutional investor acquired 59,983 shares of the company’s stock, valued at approximately $693,000.

A number of other large investors also recently bought and sold shares of the company. AQR Capital Management LLC increased its holdings in shares of Avanos Medical by 46.4% in the 1st quarter. AQR Capital Management LLC now owns 192,864 shares of the company’s stock valued at $2,700,000 after acquiring an additional 61,095 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Avanos Medical by 4.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,955 shares of the company’s stock worth $386,000 after purchasing an additional 1,121 shares during the period. Millennium Management LLC increased its stake in Avanos Medical by 508.3% during the first quarter. Millennium Management LLC now owns 547,740 shares of the company’s stock valued at $7,849,000 after purchasing an additional 457,703 shares during the last quarter. Empowered Funds LLC raised its holdings in shares of Avanos Medical by 5.4% during the first quarter. Empowered Funds LLC now owns 162,182 shares of the company’s stock worth $2,324,000 after purchasing an additional 8,348 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Avanos Medical by 17.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 140,810 shares of the company’s stock worth $2,018,000 after purchasing an additional 20,541 shares during the period. Institutional investors own 95.17% of the company’s stock.

Insider Activity at Avanos Medical

In related news, SVP Kerr Holbrook sold 15,000 shares of Avanos Medical stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $11.00, for a total transaction of $165,000.00. Following the sale, the senior vice president directly owned 83,860 shares in the company, valued at $922,460. The trade was a 15.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 2.64% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently commented on AVNS. Wall Street Zen raised shares of Avanos Medical from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Avanos Medical in a research note on Monday, December 22nd. Finally, Zacks Research lowered Avanos Medical from a “hold” rating to a “strong sell” rating in a report on Monday, December 1st. Two equities research analysts have rated the stock with a Sell rating, According to data from MarketBeat, the company currently has a consensus rating of “Sell”.

Avanos Medical Price Performance

Shares of NYSE:AVNS opened at $12.82 on Thursday. The firm’s 50 day moving average is $11.64 and its two-hundred day moving average is $11.60. The firm has a market capitalization of $595.15 million, a P/E ratio of -1.26 and a beta of 1.08. The company has a current ratio of 2.38, a quick ratio of 1.36 and a debt-to-equity ratio of 0.12. Avanos Medical, Inc. has a 52 week low of $9.30 and a 52 week high of $17.69.

Avanos Medical (NYSE:AVNS) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $0.22 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.12 by $0.10. Avanos Medical had a positive return on equity of 6.21% and a negative net margin of 67.00%.The business had revenue of $177.80 million during the quarter, compared to analyst estimates of $164.50 million. During the same period in the prior year, the company posted $0.33 EPS. The business’s revenue for the quarter was up 4.3% compared to the same quarter last year. Avanos Medical has set its FY 2025 guidance at 0.850-0.950 EPS. Analysts anticipate that Avanos Medical, Inc. will post 1.32 earnings per share for the current year.

Avanos Medical Company Profile

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.